← Leaderboards
Yunda Huang
Fred Hutchinson Cancer Center
$75,372,842
Attributed
$216,919,081
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $49.7M · FY2021–25$50M$37.5M$25M$12.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$216,919,081 · 2
By mechanism
UM1$213,364,808 · 1
R01$3,554,273 · 1
Top collaborators
- Peter B. Gilbert28 shared
- Holly Janes27 shared
- Maria Lemos1 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Holly Janes$70,932,400
- Lawrence Corey$859,232,520
- Margaret Juliana McElrath$601,692,649
- Georgia D Tomaras$127,423,185
Others in their field
Other Emerging Leaders on “Vaccines”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$149,372,007
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Ted Ross · University Of Georgia$71,962,304
- Tony Moody · Duke University$68,143,568
Research focus
VaccinesProtocols DocumentationLaboratoriesEfficacy TrialHiv Vaccine Trials NetworkLeadershipDesignImmuneVaccine TrialBiometryImmune ResponseHiv VaccinePreventProgramsClinical Trials NetworkClinical TrialsPreventionQuality ControlImmunologyOperationImmune FunctionPersonsValidationInfection
Grant awards (29)
SDMC: HIV Vaccine Trials Network$35,817,302
UM1 · FY2025 · AI
SDMC: HIV Vaccine Trials Network$4,411,693
UM1 · FY2025 · AI
Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1$3,554,273
R01 · FY2025 · AI · contact PI
SDMC: HIV Vaccine Trials Network$992,886
UM1 · FY2025 · AI
SDMC: HIV Vaccine Trials Network$991,756
UM1 · FY2025 · AI
SDMC: HIV Vaccine Trials Network$31,992,488
UM1 · FY2024 · AI
B Cell Bioinformatic Supplement: HIV Vaccine Trials Network (HVTN)$330,961
UM1 · FY2024 · AI
SDMC: HIV Vaccine Trials Network$28,510,098
UM1 · FY2023 · AI
CoVPN 3008 2022-2023$12,647,369
UM1 · FY2023 · AI
SDMC: HIV Vaccine Trials Network$21,460,272
UM1 · FY2022 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$14,844,618
UM1 · FY2022 · AI
SDMC: HIV Vaccine Trials Network$5,436,127
UM1 · FY2022 · AI
CoVPN Cross-Protocol Analyses$1,846,794
UM1 · FY2022 · AI
CoVPN Cross-Protocol Analyses$1,334,886
UM1 · FY2022 · AI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$1,011,819
UM1 · FY2022 · AI
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection$818,451
UM1 · FY2022 · AI
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC$477,868
UM1 · FY2022 · AI
CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine$453,649
UM1 · FY2022 · AI
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.$439,437
UM1 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older$419,442
UM1 · FY2022 · AI
CoVPN 3002 - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study in Adults to Determine the safety, Efficacy, and Immunogenicity of AZD1222 for Prevention of Covid-19$318,803
UM1 · FY2022 · AI
HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals$293,711
UM1 · FY2022 · AI
CoVPN 3003 - A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC$260,795
UM1 · FY2022 · AI
CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults$234,860
UM1 · FY2022 · AI
SDMC: HIV Vaccine Trials Network$26,398,527
UM1 · FY2021 · AI
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC$18,322,345
UM1 · FY2021 · AI
CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine$2,034,708
UM1 · FY2021 · AI
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC$673,501
UM1 · FY2021 · AI
CoVPN Cross-Protocol Analyses$589,642
UM1 · FY2021 · AI